The results suggest that some Ewing sarcomas could be detected earlier, when they are easier to treat.
With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.
Under the terms of the settlement, the lawsuit, counterclaims, and challenges to the patent in inter partes review have been dismissed.
The projects, organized by Friends of Cancer Research in the US and the Quality Assurance Initiative Pathology (QuIP) in Germany, are comparing different TMB assays.
Three vendors applied their variant calling and interpretation pipelines to the same tumor NGS panel data and came up with overlapping but different results.
Tumor sequencing tests may pick up age-associated mutations called clonal hematopoiesis, a noncancerous phenomenon that can have clinical implications.
The company said it will seek FDA approval for the assay, an expanded version of FoundationACT, as a CDx for targeted therapies and as a tumor mutation profiling assay.
After three years of work, the EXaCT-1 exome cancer test has become part of clinical cancer care at NewYork-Presbyterian, but developers have higher ambitions.
The team integrated tumor barcoding, genome editing, and ultra-deep barcode sequencing to interrogate pairwise combinations of tumor suppressor alterations.
The firm is in the midst of evaluating its strategic options and has hired Raymond James to assist in the process, which could include the sale of the firm, it said.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.